Bicara Therapeutics (BCAX) Other financing activities (2024 - 2026)

Bicara Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 243.91% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 101.61% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, up 72.26% from the prior year.
• Other financing activities retreated to $1.6 million in Q1 2026 per BCAX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $1.7 million in Q4 2025 and bottomed at $60000.0 in Q3 2024.
• The 3-year median for Other financing activities is $436000.0 (2025), against an average of $661000.0.
• Biggest YoY gain for Other financing activities was 2149.35% in 2025; the steepest drop was 89.85% in 2025.
• Year by year, Other financing activities stood at $77000.0 in 2024, then soared by 2149.35% to $1.7 million in 2025, then retreated by 8.66% to $1.6 million in 2026.
• Per Business Quant, the three latest BCAX Other financing activities figures stand at $1.6 million (Q1 2026), $1.7 million (Q4 2025), and $436000.0 (Q3 2025).